Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

Completed · Phase 4

Conditions studied: Human Immunodeficiency Virus Infection

In brief

Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disease (CVD) risk.

Key facts

Study ID
NCT01869634
Run by
University of California, Davis
People needed
37
Starts
2013-06-01
Expected to finish
2016-12-01
Last updated by the study team
2020-03-04

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.